Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv-Genotype'

Rbv-Genotype published presentations and documents on DocSlides.

Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
How to optimize treatment of G1 patients?
How to optimize treatment of G1 patients?
by KissesForYou
Prof. G. K. K. Lau 2012. Standard of care (SOC) ...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
M.W. Fried , 1 M. Buti,
M.W. Fried , 1 M. Buti,
by iamamercy
2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by webraph
Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
Prevention strategies for HIV/HCV co infection
Prevention strategies for HIV/HCV co infection
by giovanna-bartolotta
Isabelle Andrieux-Meyer, MD. Médecins Sans Front...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Chronic hepatitis C: guidelines for screening and
Chronic hepatitis C: guidelines for screening and
by aaron
treatment. Lisa M. Glass, MD. Clinical Lecturer. ...
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care
by lois-ondreau
Sameh W. Boktor, MD, MPH. Medical Epidemiologist....
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
Elbasvir
Elbasvir
by calandra-battersby
+ . Grazoprevir. +/- Ribavirin in . Treatment-N...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
by tatiana-dople
dans les génotypes 1b naïfs de traitement . (1)...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
David Fletcher, MD
David Fletcher, MD
by tatiana-dople
Department of Medicine. University of Toronto. Co...
Out With the Old and In With the New, Again?
Out With the Old and In With the New, Again?
by test
Out With the Old, In With the New. Current Standa...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...
Ledipasvir-Sofosbuvir + RBV in Decompensated Cirrhosis or Post-Liver Transplantation
Ledipasvir-Sofosbuvir + RBV in Decompensated Cirrhosis or Post-Liver Transplantation
by ahmir653
SOLAR-2. Source: . Manns. M, et al. Lancet Infect...
EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF
EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF
by hezekiah
FALDAPREVIR (BI 201335) + BI 207127 ± RIBAVIRIN. ...
Rare barometer survey The journey to diagnosis for people living with a rare disease
Rare barometer survey The journey to diagnosis for people living with a rare disease
by anya
Goals of the diagnosis survey. Measuring the . tim...
Safety and Efficacy of Daclatasvir
Safety and Efficacy of Daclatasvir
by tabitha
. Plus . Sofosbuvir. With or Without Ribavirin . ...
3D (Paritaprevir-Ritonavir-
3D (Paritaprevir-Ritonavir-
by ava
Ombitasvir + . Dasabuvir) +/- . RBV in . GT1b. PEA...
EASL 2019 HCV Conference Update
EASL 2019 HCV Conference Update
by sophia
April 10. –14. , 2019. Vienna, Austria. Disclaim...
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-I
by eloise
20. th. International AIDS Conference. • . Melb...
Hepatitis C in PWIDS London:
Hepatitis C in PWIDS London:
by obrien
PARTNERSHIP TOWARDS ELIMINATION OF A MAJOR PUBLIC ...